Table 3.
Patients with atrial fibrillation: age-sex standardised incidence rates per 1000 person years (py) of outcomes by database
| Drug | QResearch | CPRD | |||||
|---|---|---|---|---|---|---|---|
| Person years | No of events | Age-sex standardised rate per 1000 py (95% CI) | Person years | No of events | Age-sex standardised rate per 1000 py (95% CI) | ||
| Major bleeding | |||||||
| Warfarin | 72 487 | 1813 | 25.1 (24.0 to 26.3) | 18 795 | 515 | 27.5 (25.1 to 29.8) | |
| Dabigatran | 4988 | 107 | 21.8 (17.7 to 26.0) | 886 | 17 | 19.1 (10.0 to 28.3) | |
| Rivaroxaban | 12 515 | 338 | 26.5 (23.7 to 29.4) | 1844 | 66 | 36.3 (27.4 to 45.1) | |
| Apixaban | 7471 | 119 | 15.4 (12.6 to 18.3) | 768 | 22 | 29.0 (16.6 to 41.5) | |
| Intracranial bleed | |||||||
| Warfarin | 73 776 | 448 | 6.2 (5.6 to 6.7) | 19 080 | 112 | 5.9 (4.8 to 7.0) | |
| Dabigatran | 5082 | 14 | 3.0 (1.4 to 4.6) | 894 | <5 | 1.0 (0.0 to 3.0) | |
| Rivaroxaban | 12 668 | 66 | 5.1 (3.9 to 6.3) | 1865 | 15 | 8.2 (4.0 to 12.5) | |
| Apixaban | 7508 | 22 | 2.6 (1.4 to 3.7) | 774 | <5 | 5.0 (0.0 to 10.0) | |
| Haematuria | |||||||
| Warfarin | 73 105 | 585 | 8.0 (7.3 to 8.6) | 18 948 | 158 | 8.3 (7.0 to 9.6) | |
| Dabigatran | 5040 | 33 | 6.4 (4.2 to 8.6) | 890 | 7 | 7.3 (1.8 to 12.8) | |
| Rivaroxaban | 12 610 | 100 | 7.9 (6.4 to 9.5) | 1853 | 21 | 11.6 (6.6 to 16.6) | |
| Apixaban | 7498 | 33 | 4.4 (2.9 to 5.9) | 771 | 7 | 8.7 (2.1 to 15.2) | |
| Haemoptysis | |||||||
| Warfarin | 73 755 | 107 | 1.4 (1.2 to 1.7) | 19 069 | 27 | 1.4 (0.9 to 1.9) | |
| Dabigatran | 5067 | 8 | 1.4 (0.4 to 2.5) | 894 | <5 | 1.3 (0.0 to 3.8) | |
| Rivaroxaban | 12 669 | 18 | 1.4 (0.8 to 2.1) | 1866 | <5 | 1.2 (0.0 to 2.8) | |
| Apixaban | 7511 | <5 | 0.5 (0.0 to 1.1) | 774 | <5 | 1.2 (0.0 to 3.6) | |
| All gastrointestinal bleed | |||||||
| Warfarin | 73 360 | 691 | 9.5 (8.8 to 10.2) | 18 978 | 224 | 11.8 (10.3 to 13.4) | |
| Dabigatran | 5047 | 54 | 11.2 (8.2 to 14.2) | 890 | 8 | 9.4 (2.9 to 15.9) | |
| Rivaroxaban | 12 603 | 158 | 12.1 (10.2 to 14.1) | 1858 | 30 | 16.0 (10.2 to 21.9) | |
| Apixaban | 7489 | 62 | 8.2 (6.1 to 10.2) | 771 | 10 | 14.1 (5.2 to 23.0) | |
| Upper gastrointestinal bleed | |||||||
| Warfarin | 73 424 | 617 | 8.5 (7.8 to 9.1) | 18 989 | 204 | 10.7 (9.3 to 12.2) | |
| Dabigatran | 5047 | 53 | 11.0 (8.0 to 14.0) | 891 | 7 | 8.0 (2.1 to 14.0) | |
| Rivaroxaban | 12 612 | 149 | 11.5 (9.6 to 13.3) | 1858 | 29 | 15.5 (9.8 to 21.2) | |
| Apixaban | 7491 | 58 | 7.6 (5.6 to 9.7) | 772 | 9 | 12.6 (4.2 to 20.9) | |
| Rectal bleed | |||||||
| Warfarin | 73 769 | 78 | 1.1 (0.8 to 1.3) | 19 081 | 22 | 1.2 (0.7 to 1.7) | |
| Dabigatran | 5082 | <5 | 0.3 (0.0 to 0.8) | 893 | <5 | 1.4 (0.0 to 4.0) | |
| Rivaroxaban | 12 670 | 9 | 0.7 (0.2 to 1.1) | 1866 | <5 | 0.6 (0.0 to 1.6) | |
| Apixaban | 7509 | 5 | 0.6 (0.1 to 1.2) | 773 | <5 | 1.5 (0.0 to 4.5) | |
| Ischaemic stroke | |||||||
| Warfarin | 59 343 | 794 | 13.5 (12.6 to 14.5) | 15 349 | 225 | 14.7 (12.8 to 16.6) | |
| Dabigatran | 3744 | 58 | 15.9 (11.8 to 20.1) | 642 | 7 | 11.4 (2.7 to 20.2) | |
| Rivaroxaban | 10 278 | 128 | 12.0 (9.9 to 14.1) | 1434 | 34 | 23.6 (15.5 to 31.7) | |
| Apixaban | 5573 | 86 | 15.2 (11.9 to 18.5) | 535 | 9 | 16.4 (5.5 to 27.3) | |
| Venous thromboembolism | |||||||
| Warfarin | 69 569 | 215 | 3.1 (2.7 to 3.5) | 17 676 | 68 | 3.8 (2.9 to 4.8) | |
| Dabigatran | 4921 | 6 | 1.2 (0.2 to 2.2) | 846 | <5 | 1.3 (0.0 to 3.9) | |
| Rivaroxaban | 11 992 | 50 | 4.1 (2.9 to 5.2) | 1726 | 12 | 6.7 (2.8 to 10.6) | |
| Apixaban | 7230 | 19 | 2.5 (1.3 to 3.6) | 726 | 5 | 6.8 (0.6 to 13.0) | |
| Mortality | |||||||
| Warfarin | 73 839 | 3183 | 44.6 (43.0 to 46.1) | 19 094 | 780 | 41.7 (38.7 to 44.6) | |
| Dabigatran | 5083 | 212 | 43.1 (37.3 to 49.0) | 894 | 38 | 41.9 (28.4 to 55.5) | |
| Rivaroxaban | 12 679 | 757 | 54.6 (50.6 to 58.6) | 1866 | 112 | 53.2 (42.9 to 63.4) | |
| Apixaban | 7511 | 472 | 53.5 (48.4 to 58.5) | 774 | 56 | 61.9 (45.0 to 78.9) | |